149069-37-4

Usage

Structure

Benzene derivative with a fluorine atom at the 1 position and a 4-iodobutyl group at the 4 position

Applications

Organic synthesis, pharmaceutical research

Use

Starting material for the synthesis of various fluorinated and iodinated compounds

Relevance

Useful building block for the development of new drugs and pharmaceuticals

Safety concerns

Potential health hazards and environmental risks if not managed properly

Handling

Requires careful handling and proper management to minimize risks

Upstream product

• 89326-70-5 1-bromo-4-(4-fluorophenyl)-butane 
• 352-13-6 4-flourophenylmagnesium bromide 
• 462-06-6 fluorobenzene 
• 366-77-8 4-(4-fluorophenyl)-4-oxopropionic acid 

Downstream Products

• 129281-28-3 1-(4-(4-fluorophenyl)butyl)-4-(pyridin-2-yl)piperazine 
• 1359849-90-3 1-(4-chlorophenyl)-4-(4-(4-fluorophenyl)butyl)piperazine 
• 1348724-47-9 2-(4-(4-(4-fluorophenyl)butyl)piperazin-1-yl)pyrimidine 
• 164668-08-0 4-(4'-chlorophenyl)-1-(4'-(4-fluorophenyl)butyl)piperidin-4-ol 

Relevant academic research and scientific papers

One-pot synthesis of tetralin derivatives from 3-benzoylpropionic acids: Indium-catalyzed hydrosilylation of ketones and carboxylic acids and intramolecular cyclization

This reducing system was composed of a small amount (1 mol%) of In(OAc)3, Me2PhSiH, and I2 that effectively catalyzed the hydrosilylation of two different carbonyl groups, a ketone and a carboxylic acid found in 3-benzoylpropionic acids, followed by a subsequent intramolecular cyclization that led to the one-pot preparation of tetralin derivatives.

Multi-receptor drug design: Haloperidol as a scaffold for the design and synthesis of atypical antipsychotic agents

Using haloperidol as a scaffold, new agents were designed to investigate the structural contributions of various groups to binding at CNS receptors associated with atypical antipsychotic pharmacology. It is clear that each pharmacophoric group, the butyrophenone, the piperidine and the 4-chlorophenyl moieties contributes to changes in binding to the receptors of interest. This strategy has resulted in the identification of several new agents, compounds 16, 18, 19, 23, 24 and 25, with binding profiles which satisfy our stated criteria for agents to act as potential atypical antipsychotics. This research demonstrates that haloperidol can serve as a useful lead in the identification and design of new agents that target multiple receptors associated with antipsychotic pharmacology.